UEG Week 2022

The benefit of early intervention in CD

Personalized therapy - de-escalation strategies

What is new in anti-TNFα therapy?

Treat-to-target with ustekinumab - why didn't it work?

Is IL-23 the super target?

What is the best dose of adalimumab in CD?

Treat-to-target still alive?

Enhanced treatment algorithm for the management of CD

T reg - a new therapeutic target in IBD?

VEGA - the story continues

TYK2 Deucravacitinib in ulcerative colitis

Thinking out of the box - co-medication of the elderly

Combination therapy: week 38 efficacy and safety data from the VEGA study

Small molecules in crohn's disease

Treating the patient as a whole

Explosion of new drugs

No matter what you use - treat early!

Anti-IL-23 monoclonal antibodies: is it better to target IL-23 only than IL-23 and IL-12?

Once more a shocking message: be aware of steroids!

Pharmacokinetics of ustekinumab in the STARDUST trial

Postoperative monitoring matters!

Treat-to-target strategy is superior to conventional step-care in active patients to gain remission

You can still treat severe biofailure in CD

Oral anti-integrin therapy in IBD - new data, new chances?

Longterm potential benefit of a combIo therapy

Les résultats à long terme d'une combIothérapie

Una strategia “Treat-to-target” è superiore rispetto and un approccio convenzionale nel raggiungimento della remissione in pazienti con malattia attiva

Was tun nach der Operation?

T reg - nowy cel terapeutyczny w IBD?

Anticorps anti-IL-23: est-il préferabble de cibler l'IL-23 seule plutôt que l'IL-12 et l'IL-23?

Μπορείς ακόμη να θεραπεύσεις ανθεκτική στα βιολογικά νόσο του Crohn

TYK2 Deucravacitinib bei Colitis ulcerosa

Terapia di combinazione: efficacia e sicurezza a 38 settimane nello studio VEGA

Thinking out of the box - Einfluss der Begleitmedikation bei älteren Patienten

Treating the patient as a whole

Doustna terapia antyintegrynowa - nowe dane, nowe nadzieje?

Explosión de nuevos fármacos

VEGA - l'histoire continue

Ακόμα ένα πολύ ανησυχητικό μήνυμα: Πρόσεχε τα κορτικοστεροιδή!

Ανεξάρτητα του τι θα χορηγήσεις χορήγησέ το έγκαιρα!

Small molecules nel morbo di crohn

S1P receptor modulators

1st JAK inhibitor in CD - a game changer?

Update on IL-23 inhibition in UC

Update on JAK inhibition in UC

Final efficacy and safety results from Upadacitinib 52 weeks maintenance trial in UC patients

JAK-inhibition

VEGA & LUCENT studies

Upadacitinib - induction therapy in CD

Histological response and remission induced by mirikizumab

Risankizumab in refractory CD patients

Upadacitinib maintenance therapy - final results from U-ACHIEVE

Estrasimod in moderate to severe active UC

Ozanimod works in young and old UC patient

The era of small molecules

Persistance on therapy and real-world clinical effectiveness of Tofacitinib in ulcerative colitis: data from the ENEIDA registry

The 1st JAKi in CD

Selective IL-23 blockade

VEGA & LUCENT studi clinici

The area of small molecules

Risankizumab dans la maladie de Crohn réfractaire

JAK-Inhibition

Upadacitinib - Induktionsdaten bei CD

Selective IL-23 Blockade

Risultati finali di efficacia e sicurezza a 52 settimane di Upadacitinib in colite ulcerosa

Persistenza in terapia ed efficaci clinica di Tofacitinib in colite ulcerosa: dati dal registro ENEIDA

Treating the elderly - closer surveillance and the importance of co-medication

Updated safety data on JAK inhibitors

Steroid effects as treatment goals: quality of life and steroid free remission

Urgency - putting the focus on an important endpoint!

Filgotinib is efficacious in inducing and maintaining histological remission in UC

Urgency matters!

New endpoints in IBD

Patient reported outcomes in IBD

Neue Studienendpunkte in IBD

Patienten gerichtete Endpunkte bei CED

Whats's the origin of Crohn's genetics ? The history of IL-23 receptor genetics in Europe

Explosion of Spanish contributions

Explosión de las comunicaciones españolas

Wo kommt die Crohn-Genetik her? Die Historie der IL-23 Rezeptorgenetik in Europa

Personalised therapy in IBD

Individualisierte Therapie bei CED